Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 7, 2012, Pages 707-717

  Stellas, Dimitris ^a   Patsavoudi, Evangelia ^b,c  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

^c UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

Cancer; Inhibitors; Matrix metalloproteinases; Monoclonal antibodies

Indexed keywords

BATIMASTAT; CARBOPLATIN; CD147 ANTIGEN; CGS 27023A; CLODRONIC ACID; DOXYCYCLINE; DX 2400; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; GEMCITABINE; HEAT SHOCK PROTEIN 90; INCYCLINIDE; MABC 225; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MITOXANTRONE; MONOCLONAL ANTIBODY; PACLITAXEL; PRINOMASTAT; REBIMASTAT; STROMELYSIN; TANOMASTAT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VIMENTIN;

ALZHEIMER DISEASE; ARTICLE; BLEEDING; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DYSPNEA; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; ESOPHAGUS CANCER; FEVER; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KIDNEY CARCINOMA; LIVER FUNCTION TEST; LIVER METASTASIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; NEUROBLASTOMA CELL; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOEMBOLISM; WEIGHT REDUCTION;

EID: 84866428075     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012802650246     Document Type: Article

References (114)

1. van Wart, H. E.; Birkedal-Hansen, H., The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA, 1990, 87 (14), 5578-5582.
2. Nagase, H.; Woessner, J. F., Jr., Matrix metalloproteinases. J. Biol. Chem., 1999, 274 (31), 21491-21494.
3. Galis, Z. S.; Khatri, J. J., Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res., 2002, 90 (3), 251-262.
4. Stetler-Stevenson, W. G., Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am. J. Pathol., 1996, 148 (5), 1345-1350.
5. Davies, B.; Waxman, J.; Wasan, H.; Abel, P.; Williams, G.; Krausz, T.; Neal, D.; Thomas, D.; Hanby, A.; Balkwill, F., Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res., 1993, 53 (22), 5365-5369.
6. Sans-Fons, M. G.; Sole, S.; Sanfeliu, C.; Planas, A. M., Matrix metalloproteinase-9 and cell division in neuroblastoma cells and bone marrow macrophages. Am. J. Pathol., 2010, 177 (6), 2870-2885.
7. Lagarrigue, F.; Dupuis-Coronas, S.; Ramel, D.; Delsol, G.; Tronchere, H.; Payrastre, B.; Gaits-Iacovoni, F., Matrix metalloproteinase- 9 is upregulated in nucleophosmin-anaplastic lymphoma kinase-positive anaplastic lymphomas and activated at the cell surface by the chaperone heat shock protein 90 to promote cell invasion. Cancer Res., 2010, 70 (17), 6978-6987.
8. Stetler-Stevenson, W. G., The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases- 2. Cancer Metastasis Rev 2008, 27 (1), 57-66.
9. Montgomery, A. M.; Mueller, B. M.; Reisfeld, R. A.; Taylor, S. M.; DeClerck, Y. A., Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res., 1994, 54 (20), 5467-5473.
10. Imai, H.; Hamai, K.; Komatsuda, A.; Ohtani, H.; Miura, A. B.; IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int 1997, 51 (1), 270-276.
11. Yu, Q.; Stamenkovic, I., Cell surface-localized matrix metalloproteinase- 9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev., 2000, 14 (2), 163-176.
12. Itoh, T.; Tanioka, M.; Yoshida, H.; Yoshioka, T.; Nishimoto, H.; Itohara, S., Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res., 1998, 58 (5), 1048-1051
13. Maloney, A.; Workman, P., HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther., 2002, 2 (1), 3-24.
14. Richter, K.; Buchner, J., Hsp90: chaperoning signal transduction. J. Cell Physiol., 2001, 188 (3), 281-290.
15. Hanahan, D.; Weinberg, R. A., The hallmarks of cancer. Cell, 2000, 100 (1), 57-70.
16. Eustace, B. K.; Jay, D. G., Extracellular roles for the molecular chaperone, hsp90. Cell Cycle, 2004, 3 (9), 1098-1100.
17. Stellas, D.; El Hamidieh, A.; Patsavoudi, E., Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol., 2010, 11, 51.
18. Sims, J. D.; McCready, J.; Jay, D. G., Extracellular heat shock protein (Hsp)70 and Hsp90alpha assist in matrix metalloproteinase- 2 activation and breast cancer cell migration and invasion. PLoS, One 2011, 6 (4), e18848.
19. Miyauchi, T.; Masuzawa, Y.; Muramatsu, T., The basigin group of the immunoglobulin superfamily: complete conservation of a segment in and around transmembrane domains of human and mouse basigin and chicken HT7 antigen. J. Biochem., 1991, 110 (5), 770-774.
20. Kanekura, T.; Miyauchi, T.; Tashiro, M.; Muramatsu, T., Basigin, a new member of the immunoglobulin superfamily: genes in different mammalian species, glycosylation changes in the molecule from adult organs and possible variation in the Nterminal sequences. Cell Struct. Funct., 1991, 16 (1), 23-30.
21. Davidson, B.; Goldberg, I.; Berner, A.; Kristensen, G. B.; Reich, R., EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin. Exp. Metastasis, 2003, 20 (2), 161-169.
22. Zuo, J. H.; Zhu, W.; Li, M. Y.; Li, X. H.; Yi, H.; Zeng, G. Q.; Wan, X. X.; He, Q. Y.; Li, J. H.; Qu, J. Q.; Chen, Y.; Xiao, Z. Q., Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J. Cell Biochem., 2011, 112 (9), 2508-2517.
23. Belotti, D.; Paganoni, P.; Giavazzi, R., MMP inhibitors: experimental and clinical studies. Int. J. Biol. Markers, 1999, 14 (4), 232-238.
24. DeClerck, Y. A.; Imren, S., Protease inhibitors: role and potential therapeutic use in human cancer. Eur. J. Cancer, 1994, 30A (14), 2170-2180.
25. Frant, J.; Veerendhar, A.; Chernilovsky, T.; Nedvetzki, S.; Vaksman, O.; Hoffman, A.; Breuer, E.; Reich, R., Orally active, antimetastatic, nontoxic diphenyl ether-derived carbamoylphosphonate matrix metalloproteinase inhibitors. Chem. Med. Chem., 2011, 6 (8), 1471-1477.
26. Nelson, A. R.; Fingleton, B.; Rothenberg, M. L.; Matrisian, L. M., Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol., 2000, 18 (5), 1135-1149.
27. Dufour, A.; Sampson, N. S.; Li, J.; Kuscu, C.; Rizzo, R. C.; Deleon, J. L.; Zhi, J.; Jaber, N.; Liu, E.; Zucker, S.; Cao, J., Smallmolecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res., 2011, 71 (14), 4977-4988.
28. Betz, M.; Huxley, P.; Davies, S. J.; Mushtaq, Y.; Pieper, M.; Tschesche, H.; Bode, W.; Gomis-Ruth, F. X., 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur. J. Biochem., 1997, 247 (1), 356-363.
29. Brown, P. D., Clinical studies with matrix metalloproteinase inhibitors. Apmis, 1999, 107 (1), 174-180.
30. Davies, B.; Brown, P. D.; East, N.; Crimmin, M. J.; Balkwill, F. R., A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res., 1993, 53 (9), 2087-2091.
31. Wylie, S.; MacDonald, I. C.; Varghese, H. J.; Schmidt, E. E.; Morris, V. L.; Groom, A. C.; Chambers, A. F., The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin. Exp. Metastasis, 1999, 17 (2), 111-117.
32. Low, J. A.; Johnson, M. D.; Bone, E. A.; Dickson, R. B., The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin. Cancer Res., 1996, 2 (7), 1207-1214.
33. Bu, W.; Tang, Z. Y.; Sun, F. X.; Ye, S. L.; Liu, K. D.; Xue, Q.; Chen, J.; Gao, D. M., Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogastroenterology, 1998, 45 (22), 1056-1061.
34. Watson, S. A.; Morris, T. M.; Robinson, G.; Crimmin, M. J.; Brown, P. D.; Hardcastle, J. D., Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res., 1995, 55 (16), 3629-3633.
35. Chirivi, R. G.; Garofalo, A.; Crimmin, M. J.; Bawden, L. J.; Stoppacciaro, A.; Brown, P. D.; Giavazzi, R., Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer, 1994, 58 (3), 460-464.
36. Taraboletti, G.; Garofalo, A.; Belotti, D.; Drudis, T.; Borsotti, P.; Scanziani, E.; Brown, P. D.; Giavazzi, R., Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst., 1995, 87 (4), 293-298.
37. Zervos, E. E.; Norman, J. G.; Gower, W. R.; Franz, M. G.; Rosemurgy, A. S., Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J. Surg. Res., 1997, 69 (2), 367-371.
38. Prontera, C.; Mariani, B.; Rossi, C.; Poggi, A.; Rotilio, D., Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int. J. Cancer, 1999, 81 (5), 761-766.
39. Wojtowicz-Praga, S.; Low, J.; Marshall, J.; Ness, E.; Dickson, R.; Barter, J.; Sale, M.; McCann, P.; Moore, J.; Cole, A.; Hawkins, M. J., Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest. New Drugs, 1996, 14 (2), 193-202.
40. Macaulay, V. M.; O'Byrne, K. J.; Saunders, M. P.; Braybrooke, J. P.; Long, L.; Gleeson, F.; Mason, C. S.; Harris, A. L.; Brown, P.; Talbot, D. C., Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res., 1999, 5 (3), 513-520.
41. Wojtowicz-Praga, S. M.; Dickson, R. B.; Hawkins, M. J., Matrix metalloproteinase inhibitors. Invest New Drugs 1997, 15 (1), 61-75.
42. Wojtowicz-Praga, S.; Torri, J.; Johnson, M.; Steen, V.; Marshall, J.; Ness, E.; Dickson, R.; Sale, M.; Rasmussen, H. S.; Chiodo, T. A.; Hawkins, M. J., Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol., 1998, 16 (6), 2150-2156.
43. Millar, A. W.; Brown, P. D.; Moore, J.; Galloway, W. A.; Cornish, A. G.; Lenehan, T. J.; Lynch, K. P., Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br. J. Clin. Pharmacol., 1998, 45 (1), 21-26.
44. Rosemurgy, A.; Harris, J.; Langleben, A.; Casper, E.; Goode, S.; Rasmussen, H., Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 1999, 22 (3), 247-252.
45. Goffin, J. R.; Anderson, I. C.; Supko, J. G.; Eder, J. P., Jr.; Shapiro, G. I.; Lynch, T. J.; Shipp, M.; Johnson, B. E.; Skarin, A. T., Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin. Cancer Res., 2005, 11 (9), 3417-3424.
46. Bramhall, S. R.; Hallissey, M. T.; Whiting, J.; Scholefield, J.; Tierney, G.; Stuart, R. C.; Hawkins, R. E.; McCulloch, P.; Maughan, T.; Brown, P. D.; Baillet, M.; Fielding, J. W., Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer, 2002, 86 (12), 1864-1870.
47. Groves, M. D.; Puduvalli, V. K.; Hess, K. R.; Jaeckle, K. A.; Peterson, P.; Yung, W. K.; Levin, V. A., Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol., 2002, 20 (5), 1383-1388.
48. Levin, V. A.; Phuphanich, S.; Yung, W. K.; Forsyth, P. A.; Maestro, R. D.; Perry, J. R.; Fuller, G. N.; Baillet, M., Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J. Neurooncol., 2006, 78 (3), 295-302.
49. King, J.; Zhao, J.; Clingan, P.; Morris, D., Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res., 2003, 23 (1B), 639-645.
50. Chu, Q. S.; Forouzesh, B.; Syed, S.; Mita, M.; Schwartz, G.; Cooper, J.; Curtright, J.; Rowinsky, E. K., A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest. New Drugs, 2007, 25 (4), 359-367.
51. Gatto, C.; Rieppi, M.; Borsotti, P.; Innocenti, S.; Ceruti, R.; Drudis, T.; Scanziani, E.; Casazza, A. M.; Taraboletti, G.; Giavazzi, R., BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin. Cancer Res., 1999, 5 (11), 3603-3607.
52. Board, R. E.; Thatcher, N.; Lorigan, P., Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism? Drugs, 2006, 66 (15), 1919-19131.
53. Moore, M. J.; Hamm, J.; Dancey, J.; Eisenberg, P. D.; Dagenais, M.; Fields, A.; Hagan, K.; Greenberg, B.; Colwell, B.; Zee, B.; Tu, D.; Ottaway, J.; Humphrey, R.; Seymour, L., Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 2003, 21 (17), 3296-3302.
54. Hirte, H.; Vergote, I. B.; Jeffrey, J. R.; Grimshaw, R. N.; Coppieters, S.; Schwartz, B.; Tu, D.; Sadura, A.; Brundage, M.; Seymour, L., A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/ platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol. Oncol., 2006, 102 (2), 300-308.
55. Shalinsky, D. R.; Brekken, J.; Zou, H.; McDermott, C. D.; Forsyth, P.; Edwards, D.; Margosiak, S.; Bender, S.; Truitt, G.; Wood, A.; Varki, N. M.; Appelt, K., Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999, 878, 236-270.
56. Santos, O.; McDermott, C. D.; Daniels, R. G.; Appelt, K., Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin. Exp. Metastasis, 1997, 15 (5), 499-508.
57. Shalinsky, D. R.; Brekken, J.; Zou, H.; Kolis, S.; Wood, A.; Webber, S.; Appelt, K., Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Invest. New Drugs, 1998, 16 (4), 303-313.
58. Shalinsky, D. R.; Brekken, J.; Zou, H.; Bloom, L. A.; McDermott, C. D.; Zook, S.; Varki, N. M.; Appelt, K., Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human nonsmall cell lung cancer tumors: single agent and combination chemotherapy studies. Clin. Cancer Res., 1999, 5 (7), 1905-1917.
59. Price, A.; Shi, Q.; Morris, D.; Wilcox, M. E.; Brasher, P. M.; Rewcastle, N. B.; Shalinsky, D.; Zou, H.; Appelt, K.; Johnston, R. N.; Yong, V. W.; Edwards, D.; Forsyth, P., Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res., 1999, 5 (4), 845-854.
60. Bonomi, P., Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol., 2002, 29 (1 Suppl 4), 78-86.
61. Bissett, D.; O'Byrne, K. J.; von Pawel, J.; Gatzemeier, U.; Price, A.; Nicolson, M.; Mercier, R.; Mazabel, E.; Penning, C.; Zhang, M. H.; Collier, M. A.; Shepherd, F. A., Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J. Clin. Oncol., 2005, 23 (4), 842-849.
62. Behrendt, C. E.; Ruiz, R. B., Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb. Haemost., 2003, 90 (4), 734-737.
63. Ferrante, K.; Winograd, B.; Canetta, R., Promising new developments in cancer chemotherapy. Cancer Chemother. Pharmacol., 1999, 43 Suppl, S61-S68.
64. Lockhart, A. C.; Braun, R. D.; Yu, D.; Ross, J. R.; Dewhirst, M. W.; Humphrey, J. S.; Thompson, S.; Williams, K. M.; Klitzman, B.; Yuan, F.; Grichnik, J. M.; Proia, A. D.; Conway, D. A.; Hurwitz, H. I., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 2003, 9 (2), 586-593.
65. Miller, K. D.; Saphner, T. J.; Waterhouse, D. M.; Chen, T. T.; Rush-Taylor, A.; Sparano, J. A.; Wolff, A. C.; Cobleigh, M. A.; Galbraith, S.; Sledge, G. W., A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin. Cancer Res., 2004, 10 (6), 1971-1975.
66. Poulaki, V., BMS-275291. Bristol-Myers Squibb. Curr. Opin. Investig. Drugs, 2002, 3 (3), 500-504.
67. Rizvi, N. A.; Humphrey, J. S.; Ness, E. A.; Johnson, M. D.; Gupta, E.; Williams, K.; Daly, D. J.; Sonnichsen, D.; Conway, D.; Marshall, J.; Hurwitz, H., A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin. Cancer Res., 2004, 10 (6), 1963-1970.
68. Douillard, J. Y.; Peschel, C.; Shepherd, F.; Paz-Ares, L.; Arnold, A.; Davis, M.; Tonato, M.; Smylie, M.; Tu, D.; Voi, M.; Humphrey, J.; Ottaway, J.; Young, K.; Vreckem, A. V.; Seymour, L., Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2004, 46 (3), 361-368.
69. Leighl, N. B.; Paz-Ares, L.; Douillard, J. Y.; Peschel, C.; Arnold, A.; Depierre, A.; Santoro, A.; Betticher, D. C.; Gatzemeier, U.; Jassem, J.; Crawford, J.; Tu, D.; Bezjak, A.; Humphrey, J. S.; Voi, M.; Galbraith, S.; Hann, K.; Seymour, L.; Shepherd, F. A., Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J. Clin. Oncol., 2005, 23 (12), 2831-2839.
70. Ryan, M. E.; Ramamurthy, S.; Golub, L. M., Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontol 1996, 3, 85-96.
71. Golub, L. M.; Lee, H. M.; Ryan, M. E.; Giannobile, W. V.; Payne, J.; Sorsa, T., Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv. Dent. Res., 1998, 12 (2), 12-26.
72. Lokeshwar, B. L., MMP inhibition in prostate cancer. Ann. NY Acad. Sci., 1999, 878, 271-289.
73. Fife, R. S.; Rougraff, B. T.; Proctor, C.; Sledge, G. W., Jr., Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med 1997, 130 (5), 530-534.
74. Seftor, R. E.; Seftor, E. A.; De Larco, J. E.; Kleiner, D. E.; Leferson, J.; Stetler-Stevenson, W. G.; McNamara, T. F.; Golub, L. M.; Hendrix, M. J., Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin. Exp. Metastasis, 1998, 16 (3), 217-225.
75. Greenwald, R. A.; Golub, L. M.; Ramamurthy, N. S.; Chowdhury, M.; Moak, S. A.; Sorsa, T., In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone, 1998, 22 (1), 33-38.
76. Gilbertson-Beadling, S.; Powers, E. A.; Stamp-Cole, M.; Scott, P. S.; Wallace, T. L.; Copeland, J.; Petzold, G.; Mitchell, M.; Ledbetter, S.; Poorman, R., The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a nonmetalloproteinase- dependent mechanism. Cancer Chemother. Pharmacol., 1995, 36 (5), 418-424.
77. Smith, G. N., Jr.; Mickler, E. A.; Hasty, K. A.; Brandt, K. D., Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum., 1999, 42 (6), 1140-1146.
78. Fife, R. S.; Sledge, G. W., Jr., Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J. Lab. Clin. Med., 1995, 125 (3), 407-411.
79. Duivenvoorden, W. C.; Hirte, H. W.; Singh, G., Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis 1999, 17 (1), 27-34.
80. Fife, R. S.; Sledge, G. W., Jr.; Roth, B. J.; Proctor, C., Effects of doxycycline on human prostate cancer cells in vitro. Cancer Lett., 1998, 127 (1/2), 37-41.
81. Duivenvoorden, W. C.; Hirte, H. W.; Singh, G., Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metastasis, 1997, 17 (6), 312-322.
82. Sledge, G. W., Jr.; Qulali, M.; Goulet, R.; Bone, E. A.; Fife, R., Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Inst., 1995, 87 (20), 1546-1550.
83. Fingleton, B., CMT-3. CollaGenex. Curr. Opin. Investig. Drugs, 2003, 4 (12), 1460-1467.
84. Lee, H. M.; Golub, L. M.; Cao, J.; Teronen, O.; Laitinen, M.; Salo, T.; Zucker, S.; Sorsa, T., CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer. Curr. Med. Chem., 2001, 8 (3), 257-260.
85. Selzer, M. G.; Zhu, B.; Block, N. L.; Lokeshwar, B. L., CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer. Ann. NY Acad. Sci., 1999, 878, 678-682.
86. Lokeshwar, B. L., Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers. Pharmacol. Res., 2011, 63 (2), 146-150.
87. Gu, Y.; Lee, H. M.; Simon, S. R.; Golub, L. M., Chemically modified tetracycline-3 (CMT-3): A novel inhibitor of the serine proteinase, elastase. Pharmacol. Res., 2011.
88. Syed, S.; Takimoto, C.; Hidalgo, M.; Rizzo, J.; Kuhn, J. G.; Hammond, L. A.; Schwartz, G.; Tolcher, A.; Patnaik, A.; Eckhardt, S. G.; Rowinsky, E. K., A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin. Cancer Res., 2004, 10 (19), 6512-6521.
89. Rudek, M. A.; Figg, W. D.; Dyer, V.; Dahut, W.; Turner, M. L.; Steinberg, S. M.; Liewehr, D. J.; Kohler, D. R.; Pluda, J. M.; Reed, E., Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001, 19 (2), 584-592.
90. Cianfrocca, M.; Cooley, T. P.; Lee, J. Y.; Rudek, M. A.; Scadden, D. T.; Ratner, L.; Pluda, J. M.; Figg, W. D.; Krown, S. E.; Dezube, B. J., Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J. Clin. Oncol., 2002, 20 (1), 153-159.
91. Chu, S. C.; Forouzesh, B.; Syed, S.; Mita, M.; Schwartz, G.; Copper, J.; Curtright, J.; Rowinsky, E.K. A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest. New Drugs, 2007, 25, 359-367.
92. Roelofs, A. J.; Thompson, K.; Gordon, S.; Rogers, M. J., Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res., 2006, 12 (20 Pt 2), 6222s-6230s.
93. Konstantinopoulos, P. A.; Karamouzis, M. V.; Papatsoris, A. G.; Papavassiliou, A. G., Matrix metalloproteinase inhibitors as anticancer agents. Int. J.Biochem. Cell Biol., 2008, 40 (6-7),1156-1168.
94. Stearns, M. E.; Wang, M., Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis 1998, 16 (8), 693-702.
95. Stearns, M. E., Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin. Exp. Metastasis, 1998, 16 (4), 332-339.
96. Teronen, O.; Heikkila, P.; Konttinen, Y. T.; Laitinen, M.; Salo, T.; Hanemaaijer, R.; Teronen, A.; Maisi, P.; Sorsa, T., MMP inhibition and downregulation by bisphosphonates. Ann. NY Acad. Sci., 1999, 878, 453-465.
97. Breuer, E.; Salomon, C. J.; Katz, Y.; Chen, W.; Lu, S.; Roschenthaler, G. V.; Hadar, R.; Reich, R., Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids. J. Med. Chem., 2004, 47 (11), 2826-2832.
98. Farkas, E.; Katz, Y.; Bhusare, S.; Reich, R.; Roschenthaler, G. V.; Konigsmann, M.; Breuer, E., Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group. J. Biol. Inorg. Chem., 2004, 9 (3), 307-315.
99. Reich, R.; Katz, Y.; Hadar, R.; Breuer, E., Carbamoylphosphonate matrix metalloproteinase inhibitors 3: in vivo evaluation of cyclopentylcarbamoylphosphonic acid in experimental metastasis and angiogenesis. Clin. Cancer Res., 2005, 11 (10), 3925-3929.
100. Hoffman, A.; Qadri, B.; Frant, J.; Katz, Y.; Bhusare, S. R.; Breuer, E.; Hadar, R.; Reich, R., Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. J. Med. Chem., 2008, 51 (5), 1406-1414.
101. Jacobsen, J. A.; Major Jourden, J. L.; Miller, M. T.; Cohen, S. M., To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim. Biophys. Acta, 2010, 1803 (1), 72-94.
102. Mack, G. S.; Marshall, A., Lost in migration. Nat. Biotechnol., 2010, 28 (3), 214-229.
103. Cao, Y.; Croll, T. I.; Rizzi, S. C.; Shooter, G. K.; Edwards, H.; Finlayson, K.; Upton, Z.; Dargaville, T. R., A peptidomimetic inhibitor of matrix metalloproteinases containing a tetherable linker group. J. Biomed. Mater. Res. A, 2011, 96 (4), 663-672.
104. Fingleton, B., MMPs as therapeutic targets--still a viable option? Semin. Cell Dev. Biol., 2008, 19 (1), 61-68.
105. Egeblad, M.; Werb, Z., New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002, 2 (3), 161-174.
106. Devy, L.; Huang, L.; Naa, L.; Yanamandra, N.; Pieters, H.; Frans, N.; Chang, E.; Tao, Q.; Vanhove, M.; Lejeune, A.; van Gool, R.; Sexton, D. J.; Kuang, G.; Rank, D.; Hogan, S.; Pazmany, C.; Ma, Y. L.; Schoonbroodt, S.; Nixon, A. E.; Ladner, R. C.; Hoet, R.; Henderikx, P.; Tenhoor, C.; Rabbani, S. A.; Valentino, M. L.; Wood, C. R.; Dransfield, D. T., Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res., 2009, 69 (4), 1517-1526.
107. Arroyo, A. G.; Genis, L.; Gonzalo, P.; Matias-Roman, S.; Pollan, A.; Galvez, B. G., Matrix metalloproteinases: new routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease. Curr. Pharm. Des., 2007, 13 (17), 1787-1802.
108. Basile, J. R.; Holmbeck, K.; Bugge, T. H.; Gutkind, J. S., MT1- MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J. Biol. Chem., 2007, 282 (9), 6899-6905.
109. Itoh, Y., Metalloproteinase binding proteins: WO2009097397. Expert. Opin. Ther. Pat., 2010, 20 (8), 1091-1095.
110. Pfaffen, S.; Hemmerle, T.; Weber, M.; Neri, D., Isolation and characterization of human monoclonal antibodies specific to MMP- 1A, MMP-2 and MMP-3. Exp. Cell Res., 2010, 316 (5), 836-847.
111. Pfaffen, S.; Frey, K.; Stutz, I.; Roesli, C.; Neri, D., Tumourtargeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37 (8), 1559-1565.
112. Mendelsohn, J.; Baselga, J., The EGF receptor family as targets for cancer therapy. Oncogene, 2000, 19 (56), 6550-6565.
113. Stellas, D.; Karameris, A.; Patsavoudi, E., Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Clin. Cancer Res., 2007, 13 (6), 1831-1838.
114. Sidera, K.; Gaitanou, M.; Stellas, D.; Matsas, R.; Patsavoudi, E., A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J. Biol. Chem., 2008, 283 (4), 2031-2041.